FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 302 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership MOST POPULAR FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma May 20, 2026 Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... July 2, 2021 Breast Cancer Patients with Low Breast Density May Be More Likely... January 18, 2021 BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority... August 11, 2020 Load more HOT NEWS Drug Combo JAKs Up Immunotherapy in Two Clinical Trials In Memory of Håkan Mellstedt: Former ESMO President Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive... Hiding in plain sight: How we can use immune cells to...
